Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yoannis Imbert-Fernandez

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
Genes|April 30, 2020
Transcriptomic Profiling Identifies Differentially Expressed Genes in Palbociclib-Resistant ER+ MCF7 Breast Cancer CellsLilibeth Lanceta, Conor O'Neill, Nadiia Lypova, et al.
Cancer & Metabolism|January 24, 2014
Inhibition of 6-phosphofructo-2-kinase (PFKFB3) induces autophagy as a survival mechanismAlden C Klarer, Julie O'Neal, Yoannis Imbert-Fernandez, et al.
The Journal of Biological Chemistry|February 12, 2014
Estradiol stimulates glucose metabolism via 6-phosphofructo-2-kinase (PFKFB3)Yoannis Imbert-Fernandez, Brian F Clem, Julie O'Neal, et al.
Cancer & Metabolism|December 19, 2024
PFKFB3-dependent redox homeostasis and DNA repair support cell survival under EGFR-TKIs in non-small cell lung carcinomaNadiia Lypova, Susan M Dougherty, Brian F Clem, et al.
Cancers|May 19, 2019
Targeting Palbociclib-Resistant Estrogen Receptor-Positive Breast Cancer Cells via Oncolytic VirotherapyNadiia Lypova, Lilibeth Lanceta, Alana Gibson, et al.
Molecular Cancer Therapeutics|March 4, 2010
Anacardic acid inhibits estrogen receptor alpha-DNA binding and reduces target gene transcription and breast cancer cell proliferationDavid J Schultz, Nalinie S Wickramasinghe, Margarita M Ivanova, et al.
Breast Cancer Research : BCR|June 25, 2026
Targeting PFKFB3 to enhance CDK4/6 inhibitor response in ER+ breast cancerSucheta Telang, Brian F Clem, Ariamna A Herrera Miret, et al.
Research Square|February 23, 2026
Targeting PFKFB3 to enhance CDK4/6 inhibitor response in ER+ breast cancerSucheta Telang, Brian F Clem, Ariamna A Herrera Miret, et al.
Molecular Cancer|August 25, 2012
Cytochrome c oxidase is activated by the oncoprotein Ras and is required for A549 lung adenocarcinoma growthSucheta Telang, Kristin K Nelson, Deanna L Siow, et al.
Molecular Cancer Therapeutics|May 16, 2013
Targeting 6-phosphofructo-2-kinase (PFKFB3) as a therapeutic strategy against cancerBrian F Clem, Julie O'Neal, Gilles Tapolsky, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Genes|April 30, 2020
Transcriptomic Profiling Identifies Differentially Expressed Genes in Palbociclib-Resistant ER+ MCF7 Breast Cancer CellsLilibeth Lanceta, Conor O'Neill, Nadiia Lypova, et al.
Cancer & Metabolism|January 24, 2014
Inhibition of 6-phosphofructo-2-kinase (PFKFB3) induces autophagy as a survival mechanismAlden C Klarer, Julie O'Neal, Yoannis Imbert-Fernandez, et al.
The Journal of Biological Chemistry|February 12, 2014
Estradiol stimulates glucose metabolism via 6-phosphofructo-2-kinase (PFKFB3)Yoannis Imbert-Fernandez, Brian F Clem, Julie O'Neal, et al.
Cancer & Metabolism|December 19, 2024
PFKFB3-dependent redox homeostasis and DNA repair support cell survival under EGFR-TKIs in non-small cell lung carcinomaNadiia Lypova, Susan M Dougherty, Brian F Clem, et al.
Cancers|May 19, 2019
Targeting Palbociclib-Resistant Estrogen Receptor-Positive Breast Cancer Cells via Oncolytic VirotherapyNadiia Lypova, Lilibeth Lanceta, Alana Gibson, et al.
Molecular Cancer Therapeutics|March 4, 2010
Anacardic acid inhibits estrogen receptor alpha-DNA binding and reduces target gene transcription and breast cancer cell proliferationDavid J Schultz, Nalinie S Wickramasinghe, Margarita M Ivanova, et al.
Breast Cancer Research : BCR|June 25, 2026
Targeting PFKFB3 to enhance CDK4/6 inhibitor response in ER+ breast cancerSucheta Telang, Brian F Clem, Ariamna A Herrera Miret, et al.
Research Square|February 23, 2026
Targeting PFKFB3 to enhance CDK4/6 inhibitor response in ER+ breast cancerSucheta Telang, Brian F Clem, Ariamna A Herrera Miret, et al.
Molecular Cancer|August 25, 2012
Cytochrome c oxidase is activated by the oncoprotein Ras and is required for A549 lung adenocarcinoma growthSucheta Telang, Kristin K Nelson, Deanna L Siow, et al.
Molecular Cancer Therapeutics|May 16, 2013
Targeting 6-phosphofructo-2-kinase (PFKFB3) as a therapeutic strategy against cancerBrian F Clem, Julie O'Neal, Gilles Tapolsky, et al.
Pageof 3